Sutter Health | Aetna certified as a fully insured health plan - San Francisco Business Times bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Call it mindwriting.
The combination of mental effort and state-of-the-art technology have allowed a man with immobilized limbs to communicate by text at speeds rivaling those achieved by his able-bodied peers texting on a smartphone.
Stanford University investigators have coupled artificial-intelligence software with a device, called a brain-computer interface, implanted in the brain of a man with full-body paralysis. The software was able to decode information from the BCI to quickly convert the man s thoughts about handwriting into text on a computer screen.
The man was able to write using this approach more than twice as quickly as he could using a previous method developed by the Stanford researchers, who reported those findings in 2017 in the journal eLife.
®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination
1, announced today that it has become a category-exclusive member of the Emergency Nurses Association (ENA
™) Corporate Engagement Council.
The ENA Corporate Engagement Council (CEC) is designed to support innovation, advances in emergency nursing education, research and advocacy. Together, Magnolia Medical leadership and ENA leaders from the association team, board of directors and key ENA influencers – a mix of businesses, educators and hospitals – will create new opportunities to educate the emergency nursing profession on the most recent advancements in blood culture best practices and sepsis testing accuracy. We are thrilled to partner with the Emergency Nurses Association as an active member of its Corporate Engagement Council, said Greg Bullington, CEO of Magnolia Medical. We look forward to working closely with ENA leadership to further improve patient safety and dr
CAGE Bio Initiates Phase 2 Study for Treatment of Rosacea
News provided by
Share this article
Share this article
SAN CARLOS, Calif., May 11, 2021 /PRNewswire/ CAGE Bio Inc., a biotechnology company focused on developing innovative therapies for infection, inflammation and immunology, announced dosing of the first patient in its Phase 2 clinical trial for the treatment of inflammatory lesions of rosacea.
The 12-week randomized double-blind vehicle-controlled trial is testing CAGE Bio s novel ionic-liquid based product CGB-400 Topical Gel. Patients diagnosed with moderate to severe rosacea with inflammatory lesions on their face will be enrolled in the study at four sites in the US and randomized to an active or vehicle arm.